CG
KNSA icon

Cutler Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cutler Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$4K – 6043
2021
Q2 		$4K Sell
3,000
-2,200
-42% -$33.4K ﹤0.01% 4601
2021
Q1 		$7K Buy
5,200
+2,000
+63% +$40.9K ﹤0.01% 4112
2020
Q4 		$6K Buy
+3,200
New +$56.2K ﹤0.01% 3531

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Cutler Group's KNSA Position: Q4 2021 in Review

Cutler Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2021, closing a stake of 1,500 shares — an estimated $17K sold.

Cutler Group first reported a position in KNSA in Q1 2021 and held it in 3 quarters. The position peaked at $27K in Q2 2021. 103 funds tracked by Wall St. Rank hold KNSA as of Q4 2021.

  • Cutler Group reported no remaining Kiniksa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 1,500 Kiniksa Pharmaceuticals shares in Q4 2021, an estimated $17K.
  • Cutler Group first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Cutler Group's Kiniksa Pharmaceuticals position peaked at $27K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.